A Study of ACI-24 in Adults With Down Syndrome

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2021
This study is a prospective multicenter, placebo-controlled, double-blind, randomized study to assess the effect of one dose ACI-24 versus placebo over a 74-week treatment period and 26-week safety follow-up period.
Epistemonikos ID: 641a8a8ca922bcaee8b6acbb15919cc37f68cd9d
First added on: May 07, 2024